PLRX's logo.
Ticker Symbol: PLRX

Pliant Therapeutics Inc

$16.46 - 20-11-2024 4 p.m. ET

Exchange: NASDAQ Country: US Currency: USD Asset Type: Common Stock CIK:0001746473

Company Profile

Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins that is in development for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting Phase 2a trials of PLN-74809 for the treatment of IPF and PSC. Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies.

Sector: Manufacturing
Industry: Medicinal and Botanical Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: 260 Littlefield Avenue
Website: pliantrx.com
CEO: Bernard Coulie
Tags:
  • Health Technology
  • Biotechnology
  • Manufacturing
  • Medicinal and Botanical Manufacturing

Pricing

Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $17.05
Change: $1.01 ( 6.29%)
Days Range: $15.70 - $17.16
Beta: 0.71
52wk. High: $36.64
52wk. Low: $13.23
Ytd. Change -10.68%
50 Day Moving Average: $16.21
200 Day Moving Average: $19.98
Shares Outstanding: 59834098

Valuation

Market Cap: 102.1B
PE Ratio: -6.23
EPS (TTM): -2.74

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A